Successfully completed the transfer of the Zilretta™ manufacturing technology to Patheon - on track for NDA submission in DecemberMet primary endpoint in clinical trial evaluating Zilretta in Type 2 diabetes patients with knee osteoarthritisConference call scheduled for today at 4:30 p.m. ET BURLINGTON, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced financial results for the third quarter ended September 30, 2016. "Through recent executive hires and further expansion of our commercial and sales teams, we are laying the groundwork to realize our commercialization goals for our investigational therapy, Zilretta™ (also referred to as FX006), in 2017," said Michael Clayman, M.D., President and Chief Executive Officer of Flexion. "We are looking forward to the upcoming podium presentation of Phase 3 data evaluating Zilretta in patients with osteoarthritis of the knee at the American Association of Knee and Hip Surgeons (AAHKS) meeting on November 11 th and remain on track to submit a new drug application (NDA) for Zilretta to the U.S. Food and Drug Administration in December." Third-Quarter Financial Results The company reported a net loss of $17.8 million for the third quarter of 2016, compared to a net loss of $11.1 million for the third quarter of 2015. Research and development expenses increased to $9.0 million in the third quarter of 2016, compared to $7.8 million for the same period in 2015, due to an increase in personnel and other employee-related costs for additional headcount and stock based compensation. General and administrative expenses increased to $8.4 million in the third quarter of 2016, as compared to $3.2 million for the same period in 2015, due primarily to additional costs associated with building a commercial infrastructure to effectively support the potential commercialization of Zilretta. As of September 30, 2016, the company had $161.5 million in cash, cash equivalents, and marketable securities compared to $118.6 million as of December 31, 2015.